Mesoblast (MESO) Consolidated Net Income (2015 - 2023)
Mesoblast recorded quarterly Consolidated Net Income of -$21.6 million in Q2 2023, down 15.42% quarter-over-quarter from -$18.7 million in Q1 2023, and down 2.34% year-over-year from -$22.1 million in Q2 2022.
Mesoblast's Consolidated Net Income history runs 9 years deep, the most recent figure standing at -$21.6 million for Q2 2023.
- In Q2 2023, Consolidated Net Income fell 2.34% year-over-year to -$21.6 million; the TTM figure through Dec 2024 stood at -$21.6 million (up 66.75% YoY), while the FY2025 annual figure was -$102.1 million, down 16.13% from the prior year.
- Consolidated Net Income came in at -$21.6 million for Q2 2023 at Mesoblast, down from -$18.7 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of -$9.3 million in Q3 2019 to a low of -$29.4 million in Q1 2019.
- A 5-year average of -$22.6 million and a median of -$22.2 million in 2021 frame the typical range for Consolidated Net Income.
- Across the five-year window, Consolidated Net Income soared 55.32% in 2019 and tumbled 178.18% in 2020, its largest moves.
- Mesoblast's Consolidated Net Income stood at -$29.1 million in 2019, then rose by 12.29% to -$25.5 million in 2020, then fell by 2.2% to -$26.1 million in 2021, then climbed by 5.66% to -$24.6 million in 2022, then rose by 12.4% to -$21.6 million in 2023.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$21.6 million, -$18.7 million, and -$24.6 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -21.58 Mn |
| Mar 31, 2023 | -18.69 Mn |
| Dec 31, 2022 | -24.63 Mn |
| Sep 30, 2022 | -16.99 Mn |
| Jun 30, 2022 | -21.08 Mn |
| Mar 31, 2022 | -21.39 Mn |
| Dec 31, 2021 | -26.11 Mn |
| Sep 30, 2021 | -22.77 Mn |
| Jun 30, 2021 | -20.55 Mn |
| Mar 31, 2021 | -26.71 Mn |
| Dec 31, 2020 | -25.54 Mn |
| Sep 30, 2020 | -26.00 Mn |
| Jun 30, 2020 | -20.29 Mn |
| Mar 31, 2020 | -19.17 Mn |
| Dec 31, 2019 | -29.12 Mn |
| Sep 30, 2019 | -9.35 Mn |
| Jun 30, 2019 | -27.08 Mn |
| Mar 31, 2019 | -29.38 Mn |
| Dec 31, 2018 | -30.33 Mn |
| Sep 30, 2018 | -20.92 Mn |
| Jun 30, 2018 | -22.88 Mn |
| Mar 31, 2018 | -27.99 Mn |
| Dec 31, 2017 | -32.98 Mn |
| Sep 30, 2017 | -12.82 Mn |
| Jun 30, 2017 | -35.33 Mn |
| Mar 31, 2017 | -15.97 Mn |
| Dec 31, 2016 | -26.30 Mn |
| Sep 30, 2016 | -26.01 Mn |
| Jun 30, 2016 | -116.72 Mn |
| Mar 31, 2016 | -21.12 Mn |
| Dec 31, 2015 | -22.33 Mn |